Searched for
ANTI DIABETIC SPACE
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Generic versions of key diabetic drug in market double in a monthPost patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and player...
- IOL Chemicals announces 1:5 stock split; record date soonIOL Chemicals has approved a 1:5 stock split. This will increase affordability and liquidity. Shareholders will receive 5 new shares for ev...
- Skin ailments augment derma business in retail pharmaIncreasing incidence of fungal infections, greater awareness of skin-related issues and skin care and a growing desire to look presentable ...
- Novartis India ex-chief Jawed Zia joins rival AbbottAbbott in the second largest drug maker in India but it competes with Novartis in several therapy areas like cardiovascular, and diabetes. ...
- Former Novartis India Head Jawed Zia may Join AbbottNovartis India, with domestic sales of nearly Rs 1,200 crore, has been battling it out in the Indian market with several drug companies in ...
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- ZCL raises Rupees 170 cr from Morgan Stanley PEZCL said it is a speciality pharma company focusing on niche therapeutic areas of central nervous system (CNS), anti-retroviral (ARV) and c...
- Gastrointestinal drug sales show highest incremental gain in a yearAnti-infective cough and cold medication still tops the chart, with sales totalling Rs 14,735 crore in the domestic organised retail market.
- Chronic illness sees a spurt in business opportunity for pharma marketAccording to data from AIOCD, the Indian pharma market has grown at a compound annual growth rate of 3.3% in volume terms in the past five ...
- Coming soon: Novo Nordisk’s long-lasting insulin injectionNovo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...
- Sanofi charts India-specific strategy to boost shareFrench drug maker Sanofi says it is considering an India-specific strategy to increase its share in the country’s Rs 65,000-crore drug mark...
- Bitter sweet: India sees 17% rise in sale of diabetic medicinesIndia, which is home to the largest diabetic population in the world, has recorded a 17% rise in the anti-diabetic drug segment.
Load More
